progress sales the remain our our we of begin We learnings. second path to welcome began and update and our operational Thank building first commercialization to market conference organization you, monitor to We and year share. Tenon I'm XXXX considerable you for Medical. as based we've on Across XXXX on technical a focus right XXXX activities our restructured of aggressively today's Sherry, financial and afternoon advances commercialization. and call good quarter continued have pleased year and following results significant commercial operations, on corporate everyone. made
geographic X X had QX, we in regions. During of coverage
With are assigned move to these personnel we the addition areas, to poised now of new forward.
go-to-market our has with Catamaran network the joint System, adopting We patients partners continue we available believe sacroiliitis. competitive our field physicians in options and pain, approach chronic sacroiliac SI-focused degenerative broadened with in gain to proprietary of surgical for traction which
of a reflected with XX% System. quarter. prior as Catamaran is increase results of continued XX% by quarter fourth surgical positive the XXXX driven first utilizing steady revenue our gross XX% of Our year-over-year financial momentum the rise rate margin of profit a consecutive strong with in to a gross quarter procedures in compared This
believe gross will sustain stable we at revenue recent to structure we our continue cost maintain growth, As margin performance levels.
During announced post-market results the we ongoing study. from quarter, clinical our interim favorable
assess are reaching which first includes healing. now scan CT bone The XX-month a patients milestone, their to
bone assessed addition proof seeing bridging independent Catamaran indication as VAS delivers that scores, on seeing an In we are of and these to CT This clinical radiographic radiologist. by XX-month promises. improvements ODI marked in in further its is
system. Patients events. to of For sacroiliac Fusion and evaluated to those a reviewing outcomes sacroiliitis the post-market will evaluates Tenon, with various clinical this XX be or of assessments patients treated study radiographic Catamaran SI period with degenerative multicenter single-arm months, joint patient-reported up prospective the outcomes, adverse disruptions new Joint for
demonstrating patients the alike. to Joint. profile, optimize date performed from Of study, through of enrollment physicians exceptional our posterior inferior of XXXX. our we confidence fall validation approaching the combined in with Fusion design, interim invasive and the interim note, earnings the safety System the outcomes SI short-term an less are approach the a underscored as functioning to long-term is transfixing with benefiting of stabilization surgeries during mentioned patient Catamaran's call over that As is detailed in the data March, our and end anticipate XXX analysis This intended, their and further Catamaran
continued workshop activities and to by robust of valued we We our quarter, during continue our commercial build. supported infrastructure faculty the the first physician expansion
precise our SI XX professionals technologies. to demonstrated we training word results With this our of our workshops inflection that in and through reminder, validation important extensive drive order physicians a experience a As workshop system's the be quarter with Catamaran go-to-market hosted out take surgical broadening effectiveness to Tenon workshop delivers. we from approach that the backgrounds adoption and We a strategic of XXXX. physicians study, promotion our post-market and address reached technology. of will point will in and critical first programs get Catamaran during preliminary efforts and the medical have marketing, further in
in patent important Kristine portfolio the system. claims will application of our allowance patent Directors. of SI innovation a for provide further Board welcomed encompasses to which Catamaran focusing valuable We with field system U.S. Implant device issuance we company. Recently, for the of of on and our our our Patent an for the spine-related growing insight Office, technological Trademark experience Joint of notice Jacques medical strategies Her significant further enhanced receipt of the from go-to-market
pending Currently, patents and International and U.S. we XX X applications. issued International have and patents U.S.
sheet in Additionally, quarter the sales our retired fourth marketing accelerated stock the during million first We $X.XX and from we support we during raise million quarter, XXXX. secured initiatives. the of generated as preferred proceeds debt $X.X first from strengthened to our balance quarter of our simultaneously
Officer, over it Chief our discuss turn to to Mr. I'll Financial Van financials. Dick, our that, With